BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

Rhea-AI Summary

BrightSpring Health Services (NASDAQ: BTSG) reported preliminary Q3 2025 continuing-operations results and raised full-year 2025 guidance on Oct 20, 2025. Q3 revenues were approximately $3,334M (+28.2% YoY) and Adjusted EBITDA was ~$160M (+37.2% YoY). Q3 net income was ~$37.5M versus a loss of ~$25.7M in Q3 2024. The Company increased 2025 guidance to $12.4B–$12.7B revenue and $605M–$615M Adjusted EBITDA, excluding the Community Living business and future closed acquisitions.

Other items: pharmacy segment revenue led growth (~$2,967M Q3), leverage was ~3.31x at Sept 30, 2025, and the Company expects the Community Living divestiture to close in early Q1 2026.

Positive

• Q3 revenue of $3,334M (+28.2% YoY)
• Q3 Adjusted EBITDA of $160M (+37.2% YoY)
• Raised 2025 revenue guidance to $12.4B–$12.7B (23.1%–26.1% growth)

Negative

• Leverage of ~3.31x at Sept 30, 2025 (per credit agreements)
• Company reported results are preliminary and subject to finalization before Oct 28 release

Insights

Senior Healthcare Financial Analyst

BrightSpring reports strong Q3 preliminary results and raises full-year 2025 revenue and Adjusted EBITDA guidance.

Revenue increased to $3,334 million in Q3, up 28.2% year-over-year, driven by the Pharmacy Solutions segment which reported $2,967 million in the quarter. Adjusted EBITDA rose to $160 million, a 37.2% increase, and the company moved from a prior-year net loss to a Q3 net income of $37.5 million, all on a continuing-operations basis excluding the Community Living business.

The company raised full-year 2025 guidance to $12,400–$12,700 million revenue and $605–$615 million Adjusted EBITDA, with segment-level guidance showing Pharmacy revenue of $10,950–$11,200 million and Provider revenue of $1,450–$1,500 million. Key quantified risks and dependencies are explicit: the results exclude the Community Living business being divested (expected close in early Q1 2026), and leverage stands at approximately 3.31x under existing credit agreements, with the divested business still included in that covenant calculation at quarter-end.

Watch items: the company will finalize unaudited results and host a conference call on October 28, 2025, which will confirm final Q3 metrics and any reconciliations to GAAP; also monitor the closing of the Community Living divestiture in early Q1 2026 and any adjustments to leverage treatment. The figures presented are preliminary and the company states it does not expect material changes when finalizing results.

LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced preliminary financial results for the third quarter ended September 30, 2025, increased Revenue and Adjusted EBITDA¹ guidance, and provided details regarding its planned third quarter earnings conference call.

Preliminary Financial Highlights
(note: all figures represent continuing operations and exclude the Community Living business)

• Revenues of approximately $3,334 million, up 28.2% compared to approximately $2,601 million in the third quarter of 2024.
• Gross Profit of approximately $392 million, up 21.3% compared to approximately $323 million in the third quarter of 2024.
• Third quarter net income of approximately $37.5 million, compared to net loss of approximately $25.7 million in the third quarter of 2024.
• Adjusted EBITDA¹ of approximately $160 million, up 37.2% compared to approximately $117 million in the third quarter of 2024.
• Planned divestiture of Community Living business to Sevita, announced on January 20, 2025, is expected to close in early Q1 2026.
• Leverage was approximately 3.31x, as calculated under our First Lien Credit Agreement and Second Lien Credit Agreement, at September 30, 2025. The results of the Community Living business are included in such calculation pursuant to our First Lien Credit Agreement and the Second Lien Credit Agreement.
• Increased 2025 Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2024 Revenue and Adjusted EBITDA results, excluding the Community Living business: 
  • Revenues of $12,400 million to $12,700 million, or 23.1% to 26.1% growth.
    • Pharmacy Segment Revenue of $10,950 million to $11,200 million, or 25.1% to 27.9% growth.
    • Provider Segment Revenue of $1,450 million to $1,500 million, or 10.0% to 13.8% growth.
  • Adjusted EBITDA² of $605 million to $615 million, or 31.5% to 33.7% growth.
    

These third quarter 2025 results are preliminary and subject to the finalization of the Company’s regular financial and accounting procedures, however, the Company does not expect its final results to materially differ from the preliminary results shown within this release. These preliminary estimates are forward-looking statements. The Company’s unaudited financial results as of the three and nine months ended September 30, 2025 are not yet finalized.

The Company will announce full third quarter results on October 28^th, and host a conference call at 4:30 p.m. Eastern Time on the same day. Management will not be discussing its financial results for the third quarter before its conference call on October 28^th. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website at https://ir.brightspringhealth.com/.

Preliminary Key Financials (for BrightSpring continuing operations)

	Three Months Ended											Nine Months Ended
	September 30, (Unaudited)											September 30, (Unaudited)
	2025				2024				%			2025				2024				%
($ in millions)
Pharmacy Solutions Revenue	$	2,967			$	2,266			31	%		$	8,289			$	6,357			30	%
Provider Services Revenue		367				336			9	%			1,071				968			11	%
Total Revenue	$	3,334			$	2,601			28	%		$	9,360			$	7,325			28	%

	Three Months Ended											Nine Months Ended
	September 30, (Unaudited)											September 30, (Unaudited)
	2025				2024				%			2025				2024				%
($ in millions)
Pharmacy Solutions segment EBITDA	$	141			$	99			42	%		$	381			$	282			35	%
Provider Services segment EBITDA		61				52			16	%			168				150			12	%
Total Segment Adjusted EBITDA	$	202			$	151			33	%		$	550			$	432			27	%
Corporate Costs		(42	)			(34	)		-				(116	)			(102	)		-
Total Company Adjusted EBITDA(1)	$	160			$	117			37	%		$	434			$	330			32	%

¹Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable financial measure prepared in accordance with GAAP.

²A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income (loss) cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

About BrightSpring Health Services

BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 460,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines, while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “target,” “guidance,” the negative version of these words, or similar terms and phrases to identify these forward-looking statements.

The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

• our operation in a highly competitive industry;
• our inability to maintain relationships with existing patient referral sources or establish new referral sources;
• changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;
• cost containment initiatives of third-party payors, including post-payment audits;
• the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;
• changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;
• our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;
• changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;
• changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;
• reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;
• compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;
• fluctuation of our results of operations on a quarterly basis;
• harm caused by labor relation matters;
• limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;
• delays in collection or non-collection of our accounts receivable, particularly during the business integration process;
• failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;
• our ability to identify, successfully complete and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of our Community Living business;
• our ability to continue to provide consistently high quality of care;
• maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;
• contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;
• effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;
• security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;
• risks related to credit card payments and other payment methods;
• potential substantial malpractice or other similar claims;
• various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;
• our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;
• factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;
• a pandemic, epidemic, or outbreak of an infectious disease;
• inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;
• our inability to adequately protect our intellectual property rights;
• risks related to our compliance with our regulatory framework;
• the interests of KKR Stockholder may conflict with our stockholders’ interests in the future;
• our substantial indebtedness;
• significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and
• repurchases of our common stock.
  

The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.

For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” including “EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.

Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Adjusted EBITDA, and Adjusted EPS are not GAAP measures of our financial performance and should not be considered as an alternative to net income (loss) as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.

Management defines EBITDA as net income (loss) from continuing operations before income tax expense (benefit), interest expense, net and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, legal costs and settlements associated with certain historical matters for PharMerica, significant projects, and management fees.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.

BrightSpring Contact:

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
ir@brightspringhealth.com

Media Contact:
Leigh White
leigh.white@brightspringhealth.com
502.630.7412

BrightSpring Health Services, Inc. and Subsidiaries Consolidated Balance Sheets September 30, 2025 and December 31, 2024 (In thousands, except share and per share data) (Unaudited and Preliminary)
		September 30, 2025				December 31, 2024
Assets
Current assets:
Cash and cash equivalents		$	140,344			$	60,954
Accounts receivable, net of allowance for credit losses			1,012,913				902,782
Inventories			639,195				636,561
Prepaid expenses and other current assets			123,978				161,310
Current assets held for sale			863,846				131,447
Total current assets			2,780,276				1,893,054
Property and equipment, net of accumulated depreciation of $387,921 and $339,892 at September 30, 2025 and December 31, 2024, respectively			175,494				180,570
Goodwill			2,370,566				2,363,884
Intangible assets, net of accumulated amortization			521,610				595,224
Operating lease right-of-use assets, net			159,589				161,032
Deferred income taxes, net			—				5,288
Other assets			41,962				39,128
Non-current assets held for sale			—				687,960
Total assets		$	6,049,497			$	5,926,140
Liabilities, Redeemable Noncontrolling Interest, and Equity
Current liabilities:
Trade accounts payable		$	954,497			$	923,926
Accrued expenses			304,046				295,746
Current portion of obligations under operating leases			38,217				38,910
Current portion of obligations under financing leases			4,727				3,463
Current portion of long-term debt			51,870				48,725
Current liabilities held for sale			196,613				117,563
Total current liabilities			1,549,970				1,428,333
Obligations under operating leases, net of current portion			128,751				129,467
Obligations under financing leases, net of current portion			10,423				6,530
Long-term debt, net of current portion			2,465,334				2,561,858
Deferred income taxes, net			10,441				—
Long-term liabilities			63,560				71,190
Non-current liabilities held for sale			—				77,177
Total liabilities			4,228,479				4,274,555
Redeemable noncontrolling interest			2,361				3,730
Shareholders' equity:
Common stock, $0.01 par value, 1,500,000,000 shares authorized, 180,685,884 and 174,245,990 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		$	1,807			$	1,742
Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024			—				—
Additional paid-in capital			1,931,616				1,866,850
Accumulated deficit			(108,569	)			(222,155	)
Accumulated other comprehensive (loss) income			(6,291	)			1,418
Total shareholders' equity			1,818,563				1,647,855
Noncontrolling interest			94				—
Total equity			1,818,657				1,647,855
Total liabilities, redeemable noncontrolling interest, and equity		$	6,049,497			$	5,926,140

BrightSpring Health Services, Inc. and Subsidiaries Consolidated Statements of Operations For the three and nine months ended September 30, 2025 and 2024 (In thousands, except per share amounts) (Unaudited and Preliminary)
		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Revenues:
Products		$	2,966,966			$	2,265,697			$	8,289,238			$	6,357,223
Services			367,140				335,532				1,070,695				968,026
Total revenues			3,334,106				2,601,229				9,359,933				7,325,249
Cost of goods			2,721,314				2,077,121				7,605,931				5,815,981
Cost of services			220,784				201,016				648,773				581,509
Gross profit			392,008				323,092				1,105,229				927,759
Selling, general, and administrative expenses			304,165				293,995				918,090				875,344
Operating income			87,843				29,097				187,139				52,415
Loss on extinguishment of debt			—				—				—				12,726
Interest expense, net			38,235				46,614				118,776				144,366
Income (loss) from continuing operations before income taxes			49,608				(17,517	)			68,363				(104,677	)
Income tax benefit			12,120				8,155				13,118				(31,464	)
Income (loss) from continuing operations, net of income taxes			37,488				(25,672	)			55,245				(73,213	)
Income from discontinued operations, net of income taxes			17,753				16,691				56,548				37,288
Net income (loss)			55,241				(8,981	)			111,793				(35,925	)
Net loss attributable to noncontrolling interests included in continuing operations			(595	)			(751	)			(1,793	)			(1,864	)
Net income (loss) attributable to BrightSpring Health Services, Inc. and subsidiaries		$	55,836			$	(8,230	)		$	113,586			$	(34,061	)
Net income (loss) per common share:
Basic income (loss) per share attributable to common shareholders:
Continuing operations		$	0.19			$	(0.13	)		$	0.28			$	(0.37	)
Discontinued operations		$	0.08			$	0.09			$	0.28			$	0.19
Net income (loss)		$	0.27			$	(0.04	)		$	0.56			$	(0.18	)
Diluted income (loss) per share attributable to common shareholders:
Continuing operations		$	0.17			$	(0.13	)		$	0.26			$	(0.37	)
Discontinued operations		$	0.09			$	0.09			$	0.26			$	0.19
Net income (loss)		$	0.26			$	(0.04	)		$	0.52			$	(0.18	)
Weighted average shares outstanding:
Basic			203,487				198,491				202,067				190,541
Diluted			217,982				198,491				218,519				190,541

BrightSpring Health Services, Inc. and Subsidiaries
Reconciliation of EBITDA and Adjusted EBITDA
For the three and nine months ended September 30, 2025 and 2024
(Unaudited and Preliminary)

The following table reconciles net income (loss) to EBITDA and Adjusted EBITDA:

($ in thousands)		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Net income (loss)		$	37,488			$	(25,672	)		$	55,245			$	(73,213	)
Income tax expense (benefit)			12,120				8,155				13,118				(31,464	)
Interest expense, net			38,235				46,614				118,776				144,366
Depreciation and amortization			40,753				40,533				123,424				119,469
EBITDA		$	128,596			$	69,630			$	310,563			$	159,158
Non-cash share-based compensation (1)			14,173				12,720				46,155				49,793
Acquisition, integration, and transaction-related costs (2)			5,462				11,766				34,811				25,328
Restructuring and divestiture-related and other costs (3)			12,212				12,904				42,493				47,642
Legal costs and settlements (4)			—				8,920				—				21,886
Significant projects (5)			—				1,000				—				2,604
Management fee (6)			—				—				—				23,381
Total adjustments		$	31,847			$	47,310			$	123,459			$	170,634
Adjusted EBITDA		$	160,443			$	116,940			$	434,022			$	329,792

(1)	Represents non-cash share-based compensation to certain members of our management and full-time employees. The nine months ended September 30, 2024 includes $15.0 million of previously unrecognized share-based compensation expense related to performance-vesting options under the 2017 Stock Plan, a portion of which vested upon completion of the IPO.
(2)	Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. The three and nine months ended September 30, 2025 includes other non-routine transaction costs of $1.1 million and $23.4 million, respectively, as compared to $0.7 and $1.4 million in the three and nine months ended September 30, 2024.
(3)	Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures. These costs include $3.8 million and $18.5 million of costs that did not meet the criteria for discontinued operations related to the Community Living divestiture for the three and nine months ended September 30, 2025, respectively, as compared to $6.2 million and $19.6 million for the three and nine months ended September 30, 2024, respectively. These costs also include $12.7 million of unamortized debt issuance costs associated with the extinguishment of our Second Lien Facility in the nine months ended September 30, 2024.
(4)	Represents settlement and defense costs associated with certain historical PharMerica litigation matters, including the Silver matter, all of which were finalized in 2024.
(5)	Represents costs associated with certain transformational projects and for the periods presented primarily included general ledger system implementation, pharmacy billing system implementation, and ransomware attack response costs, all of which were finalized in 2024.
(6)	Represents annual management fees payable to the Managers under the Monitoring Agreement through the date of the IPO, and $22.7 million of termination fees resulting from the termination of the Monitoring Agreement upon completion of the IPO Offerings. All management fees ceased following the completion of the IPO in 2024.

BrightSpring Health Services, Inc. and Subsidiaries
Reconciliation of Adjusted EPS
For the three and nine months ended September 30, 2025 and 2024
(Unaudited and Preliminary)

The following table reconciles diluted EPS to Adjusted EPS:

(shares in thousands)		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2025				2024				2025				2024
Diluted EPS		$	0.17			$	(0.13	)		$	0.26			$	(0.37	)
Non-cash share-based compensation (1)			0.07				0.06				0.21				0.25
Acquisition, integration, and transaction-related costs (1)			0.03				0.06				0.16				0.13
Restructuring and divestiture-related and other costs (1)			0.06				0.06				0.19				0.24
Legal costs and settlements (1)			—				0.04				—				0.11
Significant projects (1)			—				0.00				—				0.01
Management fee (1)			—				—				—				0.12
Income tax impact on adjustments (2)(3)			(0.03	)			(0.06	)			(0.13	)			(0.29	)
Adjusted EPS		$	0.30			$	0.03			$	0.69			$	0.20
Weighted average common shares outstanding used in calculating diluted U.S. GAAP net income (loss) per share			217,982				198,491				218,519				190,541
Weighted average common shares outstanding used in calculating diluted Non-GAAP income per share			217,982				208,694				218,519				199,930

(1)	This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.
(2)	The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment.
(3)	For the three and nine months ended September 30, 2024, the income tax impact on adjustments is inclusive of a discrete tax benefit related to the Silver matter that was finalized in connection with the signing of the settlement agreement during the second fiscal quarter of 2024.

 

FAQ

What were BrightSpring (BTSG) preliminary Q3 2025 revenues and growth?

Preliminary Q3 2025 revenues were approximately $3,334M, up 28.2% versus Q3 2024.

How much Adjusted EBITDA did BrightSpring (BTSG) report for Q3 2025?

BrightSpring reported preliminary Q3 2025 Adjusted EBITDA of about $160M, a 37.2% increase year-over-year.

What is BrightSpring's updated full-year 2025 revenue and Adjusted EBITDA guidance (BTSG)?

The Company raised 2025 guidance to $12.4B–$12.7B revenue and $605M–$615M Adjusted EBITDA, excluding Community Living.

How did BrightSpring's pharmacy and provider segments perform in Q3 2025 (BTSG)?

Pharmacy solutions revenue was ~$2,967M (+31%) and provider services revenue was ~$367M (+9%) in Q3 2025.

When will BrightSpring (BTSG) release final Q3 2025 results and host its earnings call?

Final Q3 results and an earnings conference call are scheduled for October 28, 2025 at 4:30 PM ET.

Does BrightSpring (BTSG) expect the Community Living divestiture to close soon?

Yes; the Company expects the Community Living divestiture to Sevita to close in early Q1 2026.